Evolutionary Oncology: A New Research Validates This Approach in Preclinical Models

/in , /by

Researchers at Trinity College Dublin and Moffitt Cancer Center have uncovered a promising prostate cancer breakthrough: radiation-resistant tumor cells become unexpectedly vulnerable to attack by natural killer (NK) immune cells, presenting a strategic “evolutionary double-bind” that could transform treatment approaches. This discovery challenges traditional views of therapy resistance, showing that when prostate cancer cells adapt […]

Read more

UPDATE: VIR-5500 Results From Phase 1 Trial Look Very Promising

/in , , /by

Recent clinical data from a Phase 1 dose-escalation trial highlight VIR-5500 as a highly promising therapeutic candidate for patients with heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC). VIR-5500 is a dual-masked, bispecific T-cell engager designed to selectively target the prostate-specific membrane antigen (PSMA) while minimizing systemic toxicity. The therapy employs a specialized PRO-XTEN masking technology […]

Read more

A New Frontier: Magnetic Nanoparticle Hyperthermia for Solid Tumors

/in , , /by

In November 2025, Mayo Clinic in Rochester, Minnesota installed the first magnetic nanoparticle hyperthermia system in the United States for cancer research. The first patient was treated in December 2025, marking a major step toward bringing a long‑overlooked concept into the modern, heavily pretreated cancer landscape. Hyperthermia, the therapeutic use of heat, has been studied […]

Read more

Genomic Alterations and LuPSMA Outcomes in mCRPC: A Prognostic Insight

/in /by

Genomic alterations like TP53, PTEN, and RB1 mutations are prevalent in metastatic castration-resistant prostate cancer (mCRPC), yet their impact on response to 177Lu-PSMA-617 (LuPSMA, Pluvicto) radioligand therapy remains underexplored. A recent retrospective study published in the Journal of Nuclear Medicine analyzed 72 mCRPC patients treated with at least one cycle of LuPSMA between October 2022 […]

Read more

FDA Abandons Two-Trial Standard: Implications for Drug Development

/in /by

The FDA announced on February 18, 2026, that it will no longer require two pivotal clinical trials for new drug approvals, establishing a single-trial approach as the default standard. In a New England Journal of Medicine perspective, FDA leaders argued that the “two-trial dogma”, unchallenged since the 1960s, is obsolete given advances in biology, statistical […]

Read more

Ultrasound Nanobubbles Crack Prostate Cancer’s Collagen Fortress Improving Immunotherapy Penetration

/in , , /by

Researchers at Case Western Reserve University used tiny ultrasound-activated nanobubbles to dismantle the tough collagen walls that shield solid tumors from treatments. These “fortresses” made of stiff, crosslinked collagen block immune cells and drugs from reaching cancer cells deep inside, a major hurdle in fighting aggressive tumors like prostate cancer. The nanobubbles, filled with inert […]

Read more

SHR-4394: Phase 1/2 Trial Explores CDK4/6 Inhibition in Metastatic Prostate Cancer Combinations

/in , , , /by

A promising Phase 1/2 clinical trial  is investigating SHR-4394, a selective CDK4/6 inhibitor, combined with anti-tumor therapies such as rezvilutamide, HRS-5041, or tazemetostat in men with metastatic prostate cancer. CDK4/6 inhibitors like SHR-4394 block a key pathway that makes prostate cancer cells grow out of control. This pathway uses proteins called cyclin D, CDK4/6, and […]

Read more

BG-C0979: Pioneering Phase 1 Trial Targets ADAM9 in Advanced Solid Tumors, Including CRPC

/in , , , , /by

A first-in-human Phase 1 clinical trial is underway to evaluate BG-C0979, a novel antibody-drug conjugate (ADC) designed for adults with advanced solid tumors. This open-label study focuses on assessing the drug’s safety, tolerability, pharmacokinetics, and early signs of antitumor activity through dose escalation and potential expansion phases. BG-C0979 targets ADAM9, a disintegrin and metalloproteinase enzyme […]

Read more